Terminally modified rna
AssigneeModernaTX, Inc.
InventorsTirtha CHAKRABORTY, Stephane BANCEL, Stephen G. HOGE, Atanu ROY, Antonin DE FOUGEROLLES, Noubar B. AFEYAN
Life of this patent
Estimating the term…
Abstract
The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules via optimization of their terminal architecture.
Claims20
1-56. (canceled)
A lipid nanoparticle comprising an mRNA, wherein the mRNA comprises
- (a) a 5′ untranslated region (5′UTR);
- (b) a region of linked nucleosides encoding a polypeptide of interest;
- (c) a 3′ untranslated region (3′UTR) comprising at least one microRNA binding site;
- and
- (d) a 3′ tailing region of linked nucleosides;
- and wherein the mRNA comprises modified nucleosides.
The lipid nanoparticle of claim 56, wherein each uridine in the mRNA is a pseudouridine analog.
The lipid nanoparticle of claim 56, wherein the polypeptide of interest is a therapeutic protein, cytokine, growth factor, antibody or a fusion protein.
The lipid nanoparticle of claim 56, wherein the mRNA further comprises a 5′ cap structure.
The lipid nanoparticle of claim 56, wherein the 5′ UTR comprises a translation initiation sequence selected from a group consisting of a Kozak sequence and an internal ribosome entry site (IRES).
The lipid nanoparticle of claim 56, wherein the 3′ tailing region comprises a poly A tail of at least 100, at least 120 or at least 140 nucleosides.
Dependencies are inferred from the claim text.